Clarithromycin Tablet Dosing
For adults, the standard clarithromycin dose is 250-500 mg twice daily for immediate-release tablets or 1000 mg once daily for extended-release tablets, with dose reductions required in severe renal impairment (50% reduction if CrCl <30 mL/min) but no adjustment needed for hepatic impairment unless renal function is also compromised 1.
Adult Dosing
Immediate-Release Tablets
- Standard dose: 250-500 mg orally twice daily 2
- Duration: Varies by indication (typically 7-14 days)
- Administration: Can be taken with or without food
Extended-Release Tablets
- Standard dose: 1000 mg (two 500 mg tablets) once daily 1
- Specific indications:
- Acute bacterial exacerbation of chronic bronchitis: 1 gram daily for 7 days
- Acute maxillary sinusitis: 1 gram daily for 14 days
- Community-acquired pneumonia: 1 gram daily for 7 days
- Critical administration requirement: Must be taken with food; tablets must be swallowed whole—do not crush, chew, or break 1
Pediatric Dosing
Standard pediatric dose: 15 mg/kg/day divided twice daily (maximum 500 mg per dose)
A safety study demonstrated that clarithromycin remains well-tolerated even at doses exceeding 15 mg/kg/day, with 26% of children receiving ≥30 mg/kg/day showing no significant increase in adverse events 3. However, the standard recommended dose remains 15 mg/kg/day.
Renal Impairment Adjustments
Severe renal impairment (CrCl <30 mL/min): Reduce dose by 50% 2, 1
Moderate renal impairment (CrCl 30-60 mL/min):
- No adjustment needed for standard therapy
- Exception: Reduce dose by 50% if taking concomitant atazanavir or ritonavir-containing regimens 1
Severe renal impairment with atazanavir/ritonavir: Reduce dose by 75% 1
The rationale for dose reduction in renal impairment is that renal clearance increases from approximately 111 mL/min in healthy individuals to 170 mL/min in those with hepatic impairment, but decreases significantly with renal dysfunction, leading to drug accumulation 2, 4.
Hepatic Impairment Adjustments
No dose adjustment is required for hepatic impairment alone 5, 4.
Research demonstrates that moderate to severe hepatic impairment (Child-Pugh B and C) reduces 14-hydroxylation of clarithromycin, but this is offset by increased renal clearance, resulting in comparable steady-state concentrations of the parent drug 5. However, exercise caution in infections where the 14-hydroxy metabolite contributes to antimicrobial activity (particularly Haemophilus influenzae infections), as metabolite production is reduced 5.
Exception: If both hepatic impairment AND renal impairment coexist, follow renal dosing adjustments 5.
Drug Interaction Dosing Adjustments
With atazanavir: Reduce clarithromycin dose by 50% 1
With ritonavir-containing regimens: Follow renal impairment dosing guidelines above 2, 1
Critical Warnings
- Contraindicated in patients with history of cholestatic jaundice or hepatic dysfunction from prior clarithromycin use 1
- Avoid in patients with QT prolongation, severe bradycardia, or those taking Class IA/III antiarrhythmics 1
- Never co-administer with cisapride, pimozide, lomitapide, lovastatin, simvastatin, ergot alkaloids, or lurasidone 1
Common Pitfalls
- Forgetting food requirement for extended-release formulation: Extended-release tablets MUST be taken with food and swallowed whole 1
- Over-adjusting for hepatic impairment: Unless renal function is also compromised, hepatic impairment alone does not require dose reduction 5
- Missing drug interactions: Always check for CYP3A4 interactions, particularly with statins, calcium channel blockers, and antiretrovirals 1, 6
- Inadequate duration: Ensure appropriate treatment duration (7-14 days depending on indication) to prevent resistance 1